Sagimet Biosciences (SGMT) Competitors $6.15 -0.05 (-0.81%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$6.33 +0.18 (+2.86%) As of 05:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMT vs. TSHA, IMNM, AMLX, IOVA, PHAT, URGN, TRVI, DNTH, AVBP, and AVXLShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Taysha Gene Therapies (TSHA), Immunome (IMNM), Amylyx Pharmaceuticals (AMLX), Iovance Biotherapeutics (IOVA), Phathom Pharmaceuticals (PHAT), Urogen Pharma (URGN), Trevi Therapeutics (TRVI), Dianthus Therapeutics (DNTH), ArriVent BioPharma (AVBP), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. Its Competitors Taysha Gene Therapies Immunome Amylyx Pharmaceuticals Iovance Biotherapeutics Phathom Pharmaceuticals Urogen Pharma Trevi Therapeutics Dianthus Therapeutics ArriVent BioPharma Anavex Life Sciences Sagimet Biosciences (NASDAQ:SGMT) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation. Do institutionals and insiders have more ownership in SGMT or TSHA? 87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to SGMT or TSHA? In the previous week, Taysha Gene Therapies had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 7 mentions for Taysha Gene Therapies and 5 mentions for Sagimet Biosciences. Taysha Gene Therapies' average media sentiment score of 0.95 beat Sagimet Biosciences' score of 0.33 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Taysha Gene Therapies 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, SGMT or TSHA? Sagimet Biosciences has higher earnings, but lower revenue than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M100.00-$45.57M-$1.83-3.36Taysha Gene Therapies$8.33M94.97-$89.30M-$0.34-8.53 Do analysts prefer SGMT or TSHA? Sagimet Biosciences currently has a consensus price target of $25.67, indicating a potential upside of 317.34%. Taysha Gene Therapies has a consensus price target of $8.29, indicating a potential upside of 185.71%. Given Sagimet Biosciences' higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Taysha Gene Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, SGMT or TSHA? Sagimet Biosciences has a beta of 3.34, indicating that its share price is 234% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Is SGMT or TSHA more profitable? Sagimet Biosciences has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -1,144.97%. Sagimet Biosciences' return on equity of -39.88% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -39.88% -38.40% Taysha Gene Therapies -1,144.97%-78.44%-44.82% SummarySagimet Biosciences beats Taysha Gene Therapies on 10 of the 15 factors compared between the two stocks. Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.63M$3.12B$5.74B$10.30BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-3.3621.0376.8526.52Price / Sales100.00249.02453.0387.93Price / CashN/A45.4837.2260.63Price / Book1.219.5613.686.31Net Income-$45.57M-$53.02M$3.29B$271.37M7 Day Performance-12.64%-1.58%-0.75%0.57%1 Month Performance-18.54%2.82%3.84%6.20%1 Year Performance81.95%9.34%82.85%28.33% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences3.3516 of 5 stars$6.15-0.8%$25.67+317.3%+82.0%$201.63M$2M-3.368TSHATaysha Gene Therapies2.452 of 5 stars$3.24-3.6%$8.29+155.7%+33.0%$916.59M$8.33M-9.53180IMNMImmunome2.2168 of 5 stars$9.40-10.6%$22.89+143.5%-41.6%$915.71M$9.04M-3.0540Positive NewsAMLXAmylyx Pharmaceuticals2.3218 of 5 stars$10.44+2.4%$12.25+17.3%+337.3%$909.51M$87.37M-4.18200Analyst ForecastIOVAIovance Biotherapeutics4.3331 of 5 stars$2.38-4.4%$11.90+400.0%-78.7%$901.02M$164.07M-1.93500PHATPhathom Pharmaceuticals2.3936 of 5 stars$12.43+0.7%$17.50+40.8%-40.5%$875.45M$55.25M-2.63110URGNUrogen Pharma4.0871 of 5 stars$21.42+13.5%$32.00+49.4%+41.0%$873.47M$90.40M-6.45200Positive NewsHigh Trading VolumeTRVITrevi Therapeutics2.8392 of 5 stars$7.60+8.4%$20.11+164.6%+139.6%$853.66MN/A-18.0920Positive NewsHigh Trading VolumeDNTHDianthus Therapeutics2.8999 of 5 stars$31.80+20.0%$54.00+69.8%+49.6%$852.99M$6.24M-9.7880Gap UpHigh Trading VolumeAVBPArriVent BioPharma2.0128 of 5 stars$20.21+0.1%$39.14+93.7%-26.9%$819.09MN/A-5.0340Positive NewsAVXLAnavex Life Sciences3.6756 of 5 stars$9.35-0.5%$44.00+370.6%+60.8%$807.40MN/A-16.4040 Related Companies and Tools Related Companies Taysha Gene Therapies Competitors Immunome Competitors Amylyx Pharmaceuticals Competitors Iovance Biotherapeutics Competitors Phathom Pharmaceuticals Competitors Urogen Pharma Competitors Trevi Therapeutics Competitors Dianthus Therapeutics Competitors ArriVent BioPharma Competitors Anavex Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGMT) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
